{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040973","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.565541+00:00","generated_at":"2026-06-11T19:02:38.457635+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vera Therapeutics Q2 net loss $20.2M, cash $181M; Phase 3 atacicept trial initiated","bullets":["Net loss of $20.2M ($0.46 per share) vs $14.9M ($0.55 per share) in Q2 2022.","Cash, cash equivalents, and marketable securities of $181.0M as of June 30, 2023; funds operations to early 2026.","Positive 36-week Phase 2b ORIGIN results: significant proteinuria reduction and eGFR stabilization.","Pivotal Phase 3 ORIGIN 3 trial for IgA nephropathy initiated in June 2023.","Preliminary ORIGIN 3 data expected in first half of 2025; additional Phase 2b data in H2 2023 and 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040973","json":"https://secwatch.observer/filing/0000950170-23-040973.json","markdown":"https://secwatch.observer/filing/0000950170-23-040973.md","text":"https://secwatch.observer/filing/0000950170-23-040973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023040973/0000950170-23-040973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023040973/vera-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:02:38.457635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a218beb52d3494422930d9fee94e63181eba8fb3","claim":"Vera Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $20.2 million, or $0.46 per share, EPS $0.46 per share.","evidence_excerpt":"For the quarter ended June 30, 2023, the company reported a net loss of $20.2 million, or $0.46 per share, compared to a net loss of $14.9 million, or $0.55 per share, for the same period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023040973/0000950170-23-040973-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"a net loss of $20.2 million, or $0.46 per share"},{"label":"EPS","value":"$0.46 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}